| Title |
SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)
|
|---|---|
| Published in |
Clinical and Translational Oncology, November 2017
|
| DOI | 10.1007/s12094-017-1783-2 |
| Pubmed ID | |
| Authors |
J. Cassinello, J. Á. Arranz, J. M. Piulats, A. Sánchez, B. Pérez-Valderrama, B. Mellado, M. Á. Climent, D. Olmos, J. Carles, M. Lázaro |
| Abstract |
Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 77 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 77 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 18% |
| Other | 9 | 12% |
| Student > Bachelor | 9 | 12% |
| Student > Master | 8 | 10% |
| Student > Ph. D. Student | 6 | 8% |
| Other | 15 | 19% |
| Unknown | 16 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 31% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 12% |
| Biochemistry, Genetics and Molecular Biology | 9 | 12% |
| Unspecified | 5 | 6% |
| Nursing and Health Professions | 4 | 5% |
| Other | 8 | 10% |
| Unknown | 18 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 November 2017.
All research outputs
#14,830,566
of 23,007,887 outputs
Outputs from Clinical and Translational Oncology
#639
of 1,320 outputs
Outputs of similar age
#190,728
of 326,002 outputs
Outputs of similar age from Clinical and Translational Oncology
#26
of 41 outputs
Altmetric has tracked 23,007,887 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,320 research outputs from this source. They receive a mean Attention Score of 3.7. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 326,002 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.